Navigation Links
Loma Linda University Health's New Study Suggests Proton Therapy As a Better Option for Early-Stage Breast Cancer Patients
Date:12/18/2018

Patients with early stages of breast cancer who undergo partial breast proton irradiation treatment after a lumpectomy have better quality of life post-treatment versus whole breast irradiation, a new study suggests.

Patients with early stage breast cancer — stage zero to two — are typically treated with whole breast irradiation after removal of the cancerous tumor because there is a 30 to 40 percent change the disease will return. But partial breast proton irradiation allows physicians non-target breast tissue and other organs in close proximity to not be affected.

The study, recently published in the Cancer Medicine Journal, demonstrated patients undergoing partial breast proton irradiation reported less fatigue, fewer restrictions in daily activities, less breast pain, better cosmetic results and future perspective.

Lead researcher David A. Bush, MD, a radiation oncologist at Loma Linda University Health, said the results from the study allow physicians to now present another treatment option that places whole-person care at the forefront.

“Breast cancer patients can take comfort knowing they can receive an effective treatment that will minimize or eliminate long-term damage to vital organs and provide a better physical and emotional quality of life,” Bush said. “There is life after breast cancer, and patients should have access to the best possible quality of it.”

In an effort to minimize unnecessary side-effects and allow patients to have optimal quality of life post radiation, researchers at Loma Linda University Health studied partial breast proton therapy (PBPT) and compared the long-term health and well-being outcomes to standard whole breast treatment. PBPT uses targeted proton radiation that pinpoints the specified area needing the treatment. Once it is located, the beam of radiation only hits the target like a laser beam.

The alternative radiation treatment to partial breast proton irradiation is whole breast irradiation, where a radiation oncologist will use radiation on the entire breast, which can affect the treated breast as well as vital organs within close proximity to the breast — such as the heart, lungs or ribs — potentially yielding negative cosmetic and emotional effects causing a low quality of life.

The study, “Improved long-term patient-reported health and well-being outcomes of early-stage breast cancer treated with partial breast proton therapy,” evaluated patients from 2003 to 2012 and reported quality of life outcomes from 129 patients over the age of 40 that had early-stages of breast cancer and were five to 10 years post radiation treatment. Researchers compared patient-reported health and well-being outcomes of 57 patients treated with WBI five days a week for six weeks and 72 patients with PBPT in 10 daily fractions.

To qualify for the clinical trial, patients had to have a lumpectomy first, their tumor had to be smaller than 3 centimeters, the lymph nodes had to be negative and the surgical margins had to be clear.

Due to successful results, this treatment is now offered as an option to standard treatment at Loma Linda University Cancer Center.

Read the full story at https://www.prweb.com/releases/loma_linda_university_health_s_new_study_suggests_proton_therapy_as_a_better_option_for_early_stage_breast_cancer_patients/prweb15987130.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. Renowned Astronomer David Levy To Donate Night Sky Observation Logs to the Linda Hall Library
2. Vigilant Biosciences, Inc. Expands Board of Directors with Esteemed Dental Professional Dr. Linda Niessen
3. uBiome Appoints Dr. Philip Bourne, PhD, Director of the Data Science Institute at the University of Virginia, to its Scientific Advisory Board
4. University of Antwerp and Seton Hall University Scientists Develop New Technology and Weapon in the Fight Against Antibiotic Resistance
5. Meet the New Class of the University City Science Center’s Digital Health Accelerator
6. Philadelphia Middle School Educators Integrate STEM Learning into the Classroom with University City Science Center’s FirstHand Teacher Institute
7. Two New Members Elected to University City Science Center Board of Directors
8. MMJ International Holdings Enters Cannabis Study Agreement with BioInformatics and Genomics Center (BIG) at the University of Buffalo, New York
9. Rachel Cervantes Joins University City Science Center as VP Corporate Development
10. University City Science Center CEO Advocates for Business Accelerators Before Congress
11. ClearLight Diagnostics and Researchers at the Indiana Universitys Melvin and Bren Simon Cancer Center Announce a Collaboration to Profile the Tumor Microenvironment in Patients with Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2019)... ... January 02, 2019 , ... CellMax Life ... cells in blood, has been named as a partner in Medigen Biotech’s upcoming ... cell therapies for cancer treatment, will use CellMax Life’s circulating tumor cell platform ...
(Date:12/19/2018)... ... 19, 2018 , ... R3 Stem Cell is now offering ... in Las Vegas. Training includes facial rejuvenation, hair restoration and erectile dysfunction procedures ... aesthetics, having the training from expert, Board Certified providers is critical to instilling ...
(Date:12/18/2018)... ... December 18, 2018 , ... USDM Life Sciences, the leading ... industry, unveiled a completely redesigned website at http://www.usdm.com . The site offers ... their valued clients and business partners. , The website has a revamped ...
(Date:12/13/2018)... ... December 11, 2018 , ... Researchers at ... use to quickly detect Clostridium difficile (C. diff), a dangerous and sometimes fatal ... device that can be used onsite in doctor’s offices and nursing homes, providing ...
Breaking Biology Technology:
(Date:12/19/2018)... CITY, N.Y. (PRWEB) , ... December 19, 2018 , ... ... the most innovative products in healthcare for 2018. , PM360 is featuring the ... most innovative products and services offered to the pharmaceutical and medical device industries. ...
(Date:12/18/2018)... ... 18, 2018 , ... Nativis, Inc. , a clinical ... today announced the publication of an early feasibility study in CNS Oncology suggesting ... The publication of the study, An Early Feasibility Study of the Nativis Voyager® ...
(Date:12/13/2018)... ... 13, 2018 , ... Study Protocol Summary of QC Procedure , 1 – ... assessment performed at the site., 3 - Three photos captured with Apple iPad and ... BOX., 5 - Photos moved to eAdjudication® and submitted to Reviewers., 6 - ...
Breaking Biology News(10 mins):